TL;DR
This study investigates how QiShenYiQi pills (QSYQ), a traditional Chinese medicine, affect the absorption and metabolism of atorvastatin (ATV), a common cholesterol-lowering drug. The findings reveal that QSYQ significantly increases ATV's bioavailability when taken orally by inhibiting the expression of the Mrp2 transporter in the rat ileum, suggesting a need for clinical vigilance regarding potential drug-drug interactions.
What Problem Does This Paper Address?
Coronary heart disease (CHD) is a major health concern, and atorvastatin (ATV) is a cornerstone medication for its management. Many Chinese cardiovascular patients also use traditional Chinese medicines, such as QiShenYiQi pills (QSYQ), alongside conventional drugs like ATV. However, the potential for these co-prescriptions to alter the effectiveness or safety of ATV has not been well-studied. Specifically, ATV's absorption and metabolism are influenced by various transporters and enzymes in the gut and liver. If QSYQ affects these pathways, it could lead to altered ATV levels in the body, potentially increasing the risk of adverse effects like myopathy or rhabdomyolysis. This paper aims to elucidate the pharmacokinetic interactions between QSYQ and ATV to inform clinical practice.
Methods
The researchers employed a multi-faceted approach to investigate the interaction:
- In Vivo Pharmacokinetic Studies: Sprague-Dawley rats were divided into four groups. Two groups received ATV orally (with or without QSYQ pre-treatment), and two groups received ATV intravenously (with or without QSYQ pre-treatment). Blood samples were collected at various time points to measure the concentrations of ATV and its active metabolites (ortho-hydroxy atorvastatin (o-ATV) and para-hydroxy atorvastatin (p-ATV)) using ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
- Gene Expression Analysis (qRT-PCR): After the pharmacokinetic studies, tissue samples (liver, jejunum, and ileum) were collected to analyze the mRNA expression levels of key genes involved in ATV transport (e.g., P-glycoprotein, Mrp2, Oatp2b1) and metabolism (e.g., Cyp3A1, Cyp3A2).
- Protein Expression Analysis (Western Blot): The protein levels of P-glycoprotein in the jejunum and Mrp2 in the ileum were quantified to correlate with the observed mRNA changes and pharmacokinetic outcomes.
Datasets
Not discussed in the paper. The study utilized experimental data generated from animal models.
Key Insights and Ideas
- Oral vs. Intravenous Matters: The most striking finding is that QSYQ's effect on ATV pharmacokinetics is route-dependent. While it significantly impacts oral ATV absorption, it has no discernible effect when ATV is administered intravenously. This strongly suggests that QSYQ primarily influences intestinal absorption mechanisms.
- Mrp2 is the Key Player: The study pinpoints Mrp2 (multidrug resistance-associated protein 2) in the ileum as the primary target of QSYQ's influence. Inhibition of Mrp2 expression by QSYQ leads to reduced ATV efflux from intestinal cells back into the lumen, thereby increasing the amount of ATV available for absorption into the bloodstream.
- Metabolite Levels Reflect Transport: While QSYQ didn't significantly alter the levels of o-ATV (a major metabolite primarily formed in the liver), it did increase p-ATV levels when ATV was given orally. This, combined with the pharmacokinetic data, supports the idea that the increased ATV exposure is due to altered absorption rather than changes in hepatic metabolism.
- mRNA vs. Protein Discrepancy: The study observed a decrease in Mrp2 mRNA in the ileum, which correlated with a decrease in Mrp2 protein levels. However, for P-glycoprotein, while mRNA levels decreased in the jejunum, protein levels did not show a significant change. This highlights the complex relationship between gene and protein expression.
Key Results
- Increased Oral Bioavailability: Co-administration of QSYQ with oral ATV led to a significant increase in the area under the curve (AUC0-12h) of ATV by approximately 80% and the maximum concentration (Cmax) by about 95%.
- Elevated p-ATV: The concentration of p-ATV also increased significantly (by 154%) in rats treated orally with ATV and QSYQ.
- Reduced Mrp2 Expression: QSYQ significantly decreased the mRNA and protein expression of Mrp2 in the ileum of rats treated orally with ATV.
- No IV Effect: Intravenous administration of ATV, with or without QSYQ, showed no significant changes in the pharmacokinetic parameters of ATV or its major metabolite o-ATV.
- P-glycoprotein Changes: While mRNA for P-glycoprotein decreased in the jejunum, protein levels did not show a significant change.
Limitations and Future Work
The authors acknowledge several limitations:
- Species Specificity: The study was conducted in rats, and results may not directly translate to humans due to differences in transporter and enzyme expression and function.
- Limited Sample Size: The sample size for gene and protein expression analysis was small (n=3), which might limit the statistical power of some findings.
- Focus on Specific Tissues: The study focused on the jejunum and ileum for transporter expression. Alterations in other intestinal segments or organs might exist.
- Complex QSYQ Composition: QSYQ is a complex mixture of active ingredients, making it challenging to pinpoint the exact component(s) responsible for the observed effects.
Future work could involve:
- Human Studies: Clinical trials are needed to confirm these findings in human patients.
- Component Analysis: Investigating the specific active ingredients in QSYQ responsible for Mrp2 inhibition.
- Broader Tissue Analysis: Examining transporter and enzyme expression in other relevant tissues.
- Long-Term Effects: Assessing the long-term implications of this drug-drug interaction.
Summary updated